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Volume 53, Number 2 Abstracts 559ipsilateral to the occlusion on follow-up (P  .027) were associated with
increased risk of death. Kaplan-Meier analysis showed 7-year survival for
patients with ECA disease at follow-up was significantly worse (16.2% 
10.3% vs 79%  8.7%; P  .00001).
Conclusions: Patients with carotid occlusion frequently present with
symptoms referable to the occlusion. Eighty-six percent of neurologic events
originated from the occluded carotid, indicating that the process is not
benign. Multivariate analysis revealed no factor, specifically, concurrent
extracranial arterial disease, predictive of subsequent neurologic events.
With significant risk of death in patients found to have ipsilateral ECA
stenosis during follow-up, it seems reasonable to continue surveillance of the
occluded carotid.
Table. Risk factors and outcome
Risk factor
Contralateral
operation
Neurologic event
in follow-up Death
Prior neck irradiation 0.068 0.17 0.054a
At presentation
Amaurosis fugax 0.078a 0.76 0.44
Ipsilateral ECA 0.17 0.19 0.005
Contralateral ECA 0.005 0.56 0.014
In follow-up
Ipsilateral vert 0.3 0.019 0.29
Ipsilateral ECA 0.033 0.073 0.000b
Contralateral ECA 0.62 0.46 0.061
ECA/vertebral stenosis
or occlusion
At presentation 0.053 0.098 0.007
Progression in
follow-up
0.29 0.427 0.31
aP  .05;
bP  .05 in multivariate analysis.
Risk Modification Strategy of Acute Renal Failure in EVAR
In-Kyong Kim, MD, Muhammad A. Khan, MD, Sikandar Z. Khan, MD,
James F. McKinsey, MD, New York Presbyterian Hospital, Columbia Uni-
versity, New York, NY.
Objective: Acute renal failure (ARF) is a known complication after
endovascular aortic aneurysm repair (EVAR), with a significant long-term
consequence. However, there is no clear understanding of its etiology or
appropriate preventative measures. Our primary objective was to identify
independent risk factors of ARF after EVAR and delineate a riskmodification
strategy.
Methods: A retrospective analysis was performed on a prospectively
maintained EVAR database. Demographics, imaging, operative record,
hospital course, and follow-up information were evaluated. Univariate anal-
ysis was performed via t test or Fisher exact test. Survival curve was estimated
by Kaplan-Meier method. Binary logistic regression model was used to
identify the independent risk factors. Contrast dose cutoff was determined
by receiver operator curve (ROC) analysis.
Results: A total of 588 patients (mean age, 76.39 years; follow-up,
26.3 months) were included. ARF developed in 13 of 386 patients (3.4%)
with normal renal function and in 18 of 148 (12.2%) with chronic kidney
disease (CKD) stage 3 (P  .001). Fifty-four patients had chronic renal
failure (stage 4 or 5). Patients who developed ARF had reduced long-term
survival (P  .012 at 4 years) and increased prevalence or progression of
CKD (P  .001) at follow-up. Independent risk factors of ARF were age,
diabetes, smoking, baseline glomerular filtration rate, intraoperative contrast
iodine amount (g), and duration between preoperative CT scan and the
operation (scan duration). Preoperative medications, preoperative hydra-
tion, contrast type (iohexanol vs iodixanol), and operation-relevant ana-
tomic factors of suprarenal fixation, maximal aneurysm size, proximal neck
length, and neck diameter did not have a significant impact on development
of ARF. ROC analysis indicated the optimal cutoff for contrast iodine dosage
was 446 g (139mL of iodixanol) for all patients (C-statistic, 0.73) and 373 g
(116 mL) for patients with preoperative CKD stage 3 (C-statistic, 0.67).
There was a significant reduction of ARF by increasing the scan duration to
at least 7 days (P .004), and this beneficial reduction was maintained at 7,
14, and 30 days, and beyond. No additional benefit was seen with each
added time period after 7 days.
Conclusion: Post-EVAR ARF leads to CKD, faster renal function
decline, and higher long-term mortality. Contrast iodine dosage and scan
duration are independent risk factors that can be controlled by the surgeon.
Using less than the above threshold amount of contrast and increasing the
scan duration to at least 7 days will lead to significant reduction in ARF.
m
butcomes of Mesenteric Reinterventions for In-Stent Restenosis in
atients Treated for Atherosclerotic Mesenteric Artery Disease
iziano Tallarita, MD, Gustavo S. Oderich, MD, Peter Gloviczki, MD,
udra A. Duncan, MD, Manju Kalra, MBBS, Steven Cha, MS, Thomas C.
ower, MD, Mayo Clinic, Rochester, Minn.
Objective: Mesenteric artery stents (MAS) for chronic mesenteric
schemia (CMI) have been plagued by high restenosis and reinterventions
ates. This study reviewed the outcomes of patients treated for mesenteric
rtery in-stent restenosis (MAISR) with open surgical (OR) or redo endo-
ascular mesenteric revascularization (ER).
Methods: The clinical data of 157 patients (190MAS) treated for CMI
ere entered into a prospective database (1998-2010). Fifty-six patients
37%) developed MAISRs, defined by duplex ultrasound peak systolic
elocity 350 cm/s or angiographic stenosis 60%. We reviewed the
linical data and outcomes of patients undergoing reinterventions for
AISR. End points were procedure-related mortality and morbidity, and
ate patient survival, symptom recurrence, reintervention, and patency rates.
Results: There were 30 patients (19%) treated for MAISR, including
5 women and 5 men, with a mean age of 69  14 years. Twenty-four
atients presented with recurrent symptoms (27 chronic and 3 acute), and 6
ad asymptomatic preocclusive lesions. Twenty-six patients (87%) had en-
ovascular reintervention, including stent placement in 19 (15 uncovered
nd 4 covered) or percutaneous transluminal angioplasty (PTA) in 7. Four
atients (13%) underwentOR, including one with acute ischemia. There was
ne death (3%) in a patient with acute ischemia treated with redo stenting.
even patients (27%), all treated by ER, developed complications, including
ccess site problems in four, and distal embolization with bowel ischemia,
ongestive heart failure or SMA reocclusion in one each. Symptom improve-
ent was noted in 23 of the 24 symptomatic patients (96%). After a mean
ollow up of 29 12months, 11 patients developed a second restenosis, and
required treatment for recurrent symptoms. Rates of symptom recurrence,
estenosis, and reinterventions were 0/4, 0/4, and 0/4 for covered stents,
/7, 3/7, and 2/7 for PTA, 5/14, 8/14, and 5/14 for uncovered stents,
nd 1/4, 4/4, and 0/4 for OR. For all patients, freedom from recurrent
ymptoms, restenosis and reinterventions were 70% 10%, 50% 11% and
0% 11% at 2 years. For patients treated with ER, secondary patency rates
ere 73  11 at the same interval.
Conclusion: Nearly 40% of patients developed mesenteric in-stent
estenosis, of which half required reintervention because of symptom recur-
ence or a preocclusive lesion. Mesenteric reinterventions were associated
ith low mortality (3%), a high complication rate (27%), and excellent
ymptom improvement (96%).
uperior Patency of Covered Stents Over Bare Metal Stents in Patients
ith Chronic Mesenteric Ischemia
uke Erdoes, MD, Heather Mixon, BS, Christopher Lesar, MD, Denny
choch, MD, University of Tennessee College of Medicine, Chattanooga
nit, Chattanooga, Tenn.
Objective: Endovascular management of chronic mesenteric ischemia,
sually with stent placement, has become an accepted management strategy.
nfortunately, this therapy is plagued by poor primary patency and high
ates of restenosis, usually with the return of symptoms. Our hypothesis is
hat treatment of chronic mesenteric ischemia with covered stents is a better
reatment option than bare metal stents.
Methods: A retrospective review was done on 108 consecutive patients
uccessfully treated for chronic mesenteric ischemia with endovascular tech-
iques between October 2005 and July 2010. There were only five known
reatment failures, all of whom required open revascularization. There were
o acute endovascular failures needing emergent operation. Eleven patients
reated with balloon angioplasty alone were excluded, leaving 122 stented
essels (67 superior mesenteric artery [SMA], 52 celiac, 3 inferior mesenteric
rtery). Patency was established at defined follow-up intervals with duplex
ltrasound imaging and arteriography if available. Life-table analysis and
ilcoxon statistic were used.
Results: There were 99 bare metal stents and 23 covered stents, with
4 covered stents used as primary therapy and 9 as secondary therapy within
ailing bare metal stents. Mean age of the patients was 63 years, and 71%
ere women. Abdominal pain was present in 86%, nausea and vomiting in
1%, and weight loss in 56%. Seven patients eventually required open
esenteric revascularization and nine died, but only two of mesenteric
schemia. Secondary patency for the entire group of stented vessels was 75%
t 18 months. Primary patency for the bare metal stents at 18 months was
nly 34%, whereas the covered stents had 86% primary patency at 18 months
P  .02). Durable symptom relief and maintenance of weight were ob-
ained in 91% of the patients with patent stents.
Conclusion: These preliminary data suggest superior primary patency
f covered mesenteric vessel stents compared with bare metal stents. Cov-
red stents may be appropriate as primary therapy in patients with chronic
esenteric ischemia, and are certainly an option for use with failed or failing
are metal stents. Further study is indicated.
